| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1093/BMB/LDV013 |
| P698 | PubMed publication ID | 25935575 |
| P50 | author | Stanley C Jordan | Q96350303 |
| P2093 | author name string | Ashley Vo | |
| Jua Choi | |||
| P2860 | cites work | CD20 deficiency in humans results in impaired T cell-independent antibody responses | Q24653638 |
| The IVIg dilemma | Q47813529 | ||
| Patients treated with high-dose intravenous immunoglobulin show selective activation of regulatory T cells | Q49168156 | ||
| Pathogenic functions of B cells in autoimmune diseases: IFN-γ production joins the criminal gang. | Q51003494 | ||
| Desensitization in HLA-incompatible kidney recipients and survival. | Q51018759 | ||
| IdeS: a bacterial proteolytic enzyme with therapeutic potential | Q33321259 | ||
| Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies | Q33403607 | ||
| Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes | Q33408360 | ||
| Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin | Q33481729 | ||
| The complement system | Q34137841 | ||
| IL-6 in inflammation, immunity, and disease | Q34248105 | ||
| IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2+ regulatory T cells | Q34289318 | ||
| Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial | Q34373536 | ||
| A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation | Q35008036 | ||
| Grand challenges in B cell biology | Q35928361 | ||
| B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells | Q35946128 | ||
| Cryptic B cell response to renal transplantation | Q37150424 | ||
| Intravenous immunoglobulin a natural regulator of immunity and inflammation | Q37544139 | ||
| The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline. | Q37644840 | ||
| B-cell targeted therapies in human autoimmune diseases: an updated perspective | Q37781401 | ||
| Desensitization: achieving immune detente | Q37820683 | ||
| B-cell immunotherapeutics: emerging roles in solid organ transplantation | Q37888431 | ||
| Monitoring and managing graft health in the kidney transplant recipient | Q37898354 | ||
| Transplantation of the broadly sensitized patient: what are the options? | Q37942453 | ||
| The impact of donor-specific anti-HLA antibodies on late kidney allograft failure | Q38003049 | ||
| The role of complement in the early immune response to transplantation. | Q38013049 | ||
| Antibody-mediated vascular rejection of kidney allografts: a population-based study | Q38062614 | ||
| Desensitization in kidney transplantation: review and future perspectives | Q38195324 | ||
| Complement as a multifaceted modulator of kidney transplant injury | Q38217273 | ||
| Interleukin-10-producing B cells and the regulation of immunity | Q38227345 | ||
| Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies | Q38289398 | ||
| Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis | Q38305522 | ||
| Signaling mechanisms regulating B-lymphocyte activation and tolerance | Q38334794 | ||
| Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study | Q39883589 | ||
| Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety. | Q41527816 | ||
| Reduced T-dependent humoral immunity in CD20-deficient mice | Q42275151 | ||
| Summary of FDA antibody-mediated rejection workshop | Q42598786 | ||
| Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation | Q43181339 | ||
| Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients | Q44584357 | ||
| Quantifying the risk of incompatible kidney transplantation: a multicenter study. | Q44753304 | ||
| A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients. | Q45932199 | ||
| Complement-binding anti-HLA antibodies and kidney-allograft survival | Q46141053 | ||
| Rituximab and intravenous immune globulin for desensitization during renal transplantation | Q46477840 | ||
| Desensitization offers hope to highly HLA-sensitized patients for a longer life expectancy after incompatible kidney transplant | Q47569936 | ||
| P433 | issue | 1 | |
| P921 | main subject | kidney transplantation | Q740909 |
| P304 | page(s) | 113-125 | |
| P577 | publication date | 2015-05-01 | |
| P1433 | published in | British Medical Bulletin | Q15750363 |
| P1476 | title | Kidney transplantation in highly sensitized patients. | |
| P478 | volume | 114 |
| Q37698860 | Antibody-Mediated Rejection: A Review |
| Q37029874 | B cells in transplantation |
| Q93043095 | Clinical Prognosis of Renal Retransplant Patients: A Single-Center Experience |
| Q39118422 | Desensitization Protocol in Recipients of Deceased Kidney Donor With Donor-Specific Antibody-Low Titers |
| Q30397952 | Desensitization: Overcoming the Immunologic Barriers to Transplantation |
| Q97548411 | Effect of intravenous immunoglobulin (IVIg) on primate complement-dependent cytotoxicity of genetically engineered pig cells: relevance to clinical xenotransplantation |
| Q88177133 | Highly HLA Sensitized Kidney Transplant Patients in a Transplant Center |
| Q26766471 | Immunological risk assessment: The key to individualized immunosuppression after kidney transplantation |
| Q39107736 | Immunomodulation by hyperimmunoglobulins after solid organ transplantation: Beyond prevention of viral infection |
| Q40071190 | Management of sensitized pediatric patients prior to renal transplantation. |
| Q92263435 | Outcome of Desensitization Therapy in Immunologically High-Risk Kidney Transplantation: Single-Center Experience |
| Q38645385 | Potential Roles for C1 Inhibitor in Transplantation |
| Q49332019 | Successful Desensitization of T cell Flow Cytometry Crossmatch Positive Renal Transplant Recipients Using Plasmapheresis and Super High-Dose Intravenous Immunoglobulin. |
| Q57474722 | The efficacy and safety of anti-interleukin-6 receptor monoclonal blockade in a renal transplant patient with Castleman disease: early post-transplant outcome |
| Q42402671 | Tracing Donor-MHC Class II Reactive B cells in Mouse Cardiac Transplantation: Delayed CTLA4-Ig Treatment Prevents Memory Alloreactive B-Cell Generation |
| Q90496748 | Xenoantigen Deletion and Chemical Immunosuppression Can Prolong Renal Xenograft Survival |
Search more.